PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.
Menu
Close
PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.
Menu
Close
PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
PreComb
Predicting Patient Drug Response
to Tailor Cancer Treatments
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.
Founded in Switzerland
PreComb Therapeutics AG was founded in Hombrechtikon, Switzerland, by Jens M Kelm, Peter Steiner and Olivier Mauti. The company aimed to develop technologies bringing precision medicine benefits to cancer patients.
PreComb secured seed financing
led by Kinled Austria, High-Tech Gründerfonds (HTGF) and FiveT Capital with participation from other investors.
Initiated a clinical collaboration with Innsbruck Medical University
to advance immuno-oncology personalised medicine.
Implemented the first 3DTWIN® profiler
at the University Hospital Zurich's Department of Pathology and Molecular Pathology.
Closed a 1.3 million CHF pre-Series A funding
with investors including LongeVC, Kinled and other biotech venture capital firms.
Became a finalist in the Swiss Technology Award 2022
competing in the 'Start-ups (Rising Stars)' category.
Joined the IONOS Startup Program
to advance the 3DTWIN® technology, a fully automated drug sensitivity profiling solution for patient-derived cancer cells.
PreComb announced the close of their Series A funding round
reflecting investor confidence in their cancer technology.